Iovance Biotherapeutics, Inc. (IOVA)Healthcare | Biotechnology | San Carlos, United States | NasdaqGM
8.01 USD
-0.25
(-3.027%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 8.03 +0.02 (0.250%) ⇧ (Aug. 28, 2026, 7:52 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:29 a.m. EDT
The immediate outlook is driven by a powerful divergence between deteriorating fundamentals and aggressive speculative positioning. While the company's long-term trajectory is marred by a severe multi-year decline—dropping nearly 71% over the last nine years with just one positive annual return—the recent price action tells a different story. The stock has rallied significantly off its lows, and the options market is screaming for further upside, with traders pouring capital into deep out-of-the-money calls for late 2026 and early 2027. This suggests the market is pricing in a potential catalyst or a recovery in the pipeline that could reverse the structural decline seen in the historical data. However, the fundamental reality remains stark: the business is burning cash, has negative earnings, and faces a steep path to profitability. The short-term momentum is strong enough to justify a bullish stance for a swing trade, but investors must remain wary that the options flow may be chasing a narrative that hasn't yet been validated by the financials. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.119992 |
| AutoETS | 0.151931 |
| AutoARIMA | 0.151938 |
| MSTL | 0.156766 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 21% |
| H-stat | 10.73 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.81 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.25 |
| Revenue per Share | 0.792 |
| Market Cap | 3,628,301,312 |
| Forward P/E | -27.88 |
| Beta | 0.70 |
| Profit Margins | -89.09% |
| Website | https://www.iovance.com |
As of Aug. 22, 2026, 5:29 a.m. EDT: Speculators are aggressively positioning for a significant upside move, evidenced by massive call volume and open interest at strikes well above the current price (e.g., 17.0 and 20.0 strikes for Jan 2027 expirations showing new flow). Conversely, put activity is concentrated in the money and at-the-money strikes, suggesting a hedge against volatility rather than a bearish bet on a crash. The disparity in volume between deep out-of-the-money calls and puts indicates a speculative thesis on continued growth.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.7716894 |
| Address1 | 825 Industrial Road |
| Address2 | Suite 100 |
| All Time High | 165.0 |
| All Time Low | 1.0 |
| Ask | 4.98 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 18,385,520 |
| Average Daily Volume3 Month | 16,724,001 |
| Average Volume | 16,724,001 |
| Average Volume10Days | 18,385,520 |
| Beta | 0.701 |
| Bid | 3.76 |
| Bid Size | 1 |
| Board Risk | 4 |
| Book Value | 1.625 |
| City | San Carlos |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.01 |
| Current Ratio | 4.345 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 8.35 |
| Day Low | 7.97 |
| Debt To Equity | 6.25 |
| Display Name | Iovance Biotherapeutics |
| Earnings Call Timestamp End | 1,786,019,400 |
| Earnings Call Timestamp Start | 1,786,019,400 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -259,603,008 |
| Ebitda Margins | -0.79885 |
| Enterprise To Ebitda | -13.007 |
| Enterprise To Revenue | 10.391 |
| Enterprise Value | 3,376,632,064 |
| Eps Current Year | -0.49571 |
| Eps Forward | -0.28729 |
| Eps Trailing Twelve Months | -0.69 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.3828 |
| Fifty Day Average Change | 2.6272001 |
| Fifty Day Average Change Percent | 0.48807314 |
| Fifty Two Week Change Percent | 277.16895 |
| Fifty Two Week High | 9.36 |
| Fifty Two Week High Change | -1.3499994 |
| Fifty Two Week High Change Percent | -0.14423071 |
| Fifty Two Week Low | 1.76 |
| Fifty Two Week Low Change | 6.25 |
| Fifty Two Week Low Change Percent | 3.5511365 |
| Fifty Two Week Range | 1.76 - 9.36 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,287,149,400,000 |
| Float Shares | 394,361,458 |
| Forward Eps | -0.28729 |
| Forward P E | -27.881235 |
| Free Cashflow | -187,794,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 975 |
| Fullday Change | -0.25 |
| Fullday Change Percent | -3.02663 |
| Fullday Price | 8.03 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.48401 |
| Gross Profits | 157,287,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00342 |
| Held Percent Institutions | 0.70528 |
| Implied Shares Outstanding | 452,971,432 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,380,153,600 |
| Last Split Factor | 1:100 |
| Long Business Summary | Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. |
| Long Name | Iovance Biotherapeutics, Inc. |
| Market | us_market |
| Market Cap | 3,628,301,312 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_40424708 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -289,516,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,746,073,742 |
| Number Of Analyst Opinions | 9 |
| Open | 8.2 |
| Operating Cashflow | -264,182,000 |
| Operating Margins | -0.52264 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 650 260 7120 |
| Post Market Change | 0.019999504 |
| Post Market Change Percent | 0.2496817 |
| Post Market Price | 8.03 |
| Post Market Time | 1,787,961,179 |
| Previous Close | 8.26 |
| Price Eps Current Year | -16.158642 |
| Price Hint | 2 |
| Price To Book | 4.9292307 |
| Price To Sales Trailing12 Months | 11.16507 |
| Profit Margins | -0.89091 |
| Quick Ratio | 3.742 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | -0.25 |
| Regular Market Change Percent | -3.02663 |
| Regular Market Day High | 8.35 |
| Regular Market Day Low | 7.97 |
| Regular Market Day Range | 7.97 - 8.35 |
| Regular Market Open | 8.2 |
| Regular Market Previous Close | 8.26 |
| Regular Market Price | 8.01 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 7,679,408 |
| Return On Assets | -0.20308 |
| Return On Equity | -0.40363997 |
| Revenue Growth | 0.657 |
| Revenue Per Share | 0.792 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 452,971,432 |
| Shares Percent Shares Out | 0.22729999 |
| Shares Short | 102,940,590 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 99,892,938 |
| Short Name | Iovance Biotherapeutics, Inc. |
| Short Percent Of Float | 0.24299999 |
| Short Ratio | 5.27 |
| Source Interval | 15 |
| State | CA |
| Symbol | IOVA |
| Target High Price | 14.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 10.0 |
| Total Cash | 297,673,984 |
| Total Cash Per Share | 0.657 |
| Total Debt | 46,003,000 |
| Total Revenue | 324,968,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.69 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.74985 |
| Two Hundred Day Average Change | 4.26015 |
| Two Hundred Day Average Change Percent | 1.1360854 |
| Type Disp | Equity |
| Volume | 7,679,408 |
| Website | https://www.iovance.com |
| Zip | 94,070 |